WilmerHale advised Ocular Therapeutix^™, Inc. (Nasdaq: OCUL) (“Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, in an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475 million, before deducting underwriting discounts and commissions and other offering expenses payable by Ocular. All of the shares in the offering were sold by Ocular. Ocular expects to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund its planned open-label extension study for AXPAXLI^™ in patients with wet age-related macular degeneration (wet AMD); to fund its planned Phase 3 clinical trials of AXPAXLI for the treatment of non-proliferative diabetic retinopathy (NPDR); for investments in infrastructure, including capital expenditures to support manufacturing; for pre-commercialization activities associated with AXPAXLI, if approved; and for working capital and other general corporate purposes.

The team advising Ocular was led by Stuart Falber, Molly Fox, and Avery Reaves, and included Dave Strong, Tim Silva, Katharine Patterson, Kevin Cheng, Shanelle Doher, Sam Wizon, and Annaka Merrick.